Apimeds Pharmaceuticals US, Inc. (APUS) — Tangible Net Worth Ratio
Apimeds Pharmaceuticals US, Inc. (APUS) has a Tangible Net Worth Ratio of 100.0% as of September 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($8.16 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Apimeds Pharmaceuticals US, Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Apimeds Pharmaceuticals US, Inc. Tangible Net Worth Ratio (2023–2023)
This chart shows how Apimeds Pharmaceuticals US, Inc.'s Tangible Net Worth Ratio has changed across 1 annual periods from 2023 to 2023. As of September 2025, the ratio stands at 100.0%, reflecting net assets of $8.16 Million with intangible assets of $0.00 USD. Also explore Apimeds Pharmaceuticals US, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Apimeds Pharmaceuticals US, Inc. (2023–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for Apimeds Pharmaceuticals US, Inc. from 2023 to 2023, covering 1 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see APUS company net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 100.0% | $31.87K | $0.00 | $422.08K | — |